Multiple Opportunities with Layered Revenue Horizons
SGN NanoPharma, a Florida, USA Corp., is a cutting edge, clinical-stage, revenue generating, nanotherapeutics company that combines proprietary nanotechnologies with structural biology to generate superior medicine.
We intend to be a leading global nanomedicine company. We have developed near term and global strategies to achieve that goal.
Our near term focus is to:
(a) formulate Cannabinoids to generate ophthalmic, neural and transdermal formulations to address large unmet medical needs and,
(b) reformulate underperforming FDA approved drugs that are sub-optimal due to poor water solubility and low bioavailability.
A key component of our strategy and focus is to generate revenues via MNP Technology-based products in India and related emerging markets from the outset, while conducting proof-of-concept (POC) clinical trials for US and other regulated markets in low-cost geographies such as India.
Revenue generation via product marketing partnerships in India and emerging markets is already underway.
Proof of concept, Phase II clinical studies are expected to begin in Q2 2017.